Last reviewed · How we verify
Eculizumab+IVMP
Eculizumab inhibits the complement C5 protein to prevent inflammatory cell destruction, while IVMP (intravenous methylprednisolone) provides corticosteroid immunosuppression.
Eculizumab inhibits the complement C5 protein to prevent inflammatory cell destruction, while IVMP (intravenous methylprednisolone) provides corticosteroid immunosuppression. Used for Paroxysmal nocturnal hemoglobinuria (PNH), Atypical hemolytic uremic syndrome (aHUS), Severe autoimmune hemolytic anemia.
At a glance
| Generic name | Eculizumab+IVMP |
|---|---|
| Sponsor | Chinese PLA General Hospital |
| Drug class | Complement inhibitor + corticosteroid combination |
| Target | Complement C5 + glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Immunology / Hematology |
| Phase | FDA-approved |
Mechanism of action
Eculizumab is a C5 complement inhibitor that blocks the terminal complement cascade, preventing formation of the membrane attack complex and reducing complement-mediated hemolysis and inflammation. IVMP is a high-dose corticosteroid that suppresses immune cell activation and proliferation. Together, this combination targets both complement-driven and steroid-responsive immune pathways.
Approved indications
- Paroxysmal nocturnal hemoglobinuria (PNH)
- Atypical hemolytic uremic syndrome (aHUS)
- Severe autoimmune hemolytic anemia
Common side effects
- Meningococcal infection
- Infusion reactions
- Hyperglycemia
- Immunosuppression-related infections
- Hypertension
Key clinical trials
- Therapy in the Acute Phase of NMOSD: A Multicenter Prospective Real-World Study (PHASE4)
- Modified Zipper Therapy for AQP4-IgG Positive Neuromyelitis Optica Spectrum Disorder (PHASE4)
- Eculizumab For the Acute Attack of Neuromyelitis Optica Spectrum Disorder (PHASE2)
- Efficacy and Safety of Monoclonal Antibody in Acute Phase of Neuromyelitis Optica Spectrum Disorder
- Eculizumab For Acute Attack of Neuromyelitis Optica Spectrum Disorder (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Eculizumab+IVMP CI brief — competitive landscape report
- Eculizumab+IVMP updates RSS · CI watch RSS
- Chinese PLA General Hospital portfolio CI